Products and New Molecular Entities
Boehringer Ingelheim has brought a range of successful products from own drug discovery to market. A number of these drugs have either achieved blockbuster status with annual sales exceeding one billion US Dollar or have blockbuster potential. Continuously, our improvement initiatives have increased our research productivity and have resulted in a well-balanced pipeline showing a substantial number of new molecular entities and a high share of products in late phase development.
Successful Products from our own Research & Development
| Product name
|
First launch
|
Active ingredient
|
Indication
|
|---|---|---|---|
| Pradaxa®
|
2008
|
dabigatran etexilate
|
Prevention of venous thromboembolic events (VTE) in adults
|
|
Spiriva®
Respimat Soft Mist™ Inhaler
Spiriva®
|
2007
2002
|
tiotropium |
COPD |
| Micardis® | 1998 | telmisartan | Essential hypertension |
|
Sifrol® / Mirapex® / Mirapexin® |
2006
1997 |
pramipexole |
Restless legs syndrome (RLS)
|
| Viramune® | 1996 | nevirapine | HIV/AIDS |
Promising Compounds in our Pipeline - Examples
| Clinical phase
|
Compound*
|
Indication
|
Therapeutic principle
|
Mode of action
|
|---|---|---|---|---|
| Phase III | Dabigatran etexilate
(Pradaxa®)
|
Stroke Prevention in atrial fibrillation
|
Anticoagulation | Oral direct inhibition of Thrombin
|
|
Acute venous thrombo-embolism (VTE)/ Secondary VTE
|
||||
| Phase III |
Linagliptin
(Ondero®)
|
Diabetes mellitus
type II |
DPP-IV antagonist
|
Dipeptidylpeptidase-IV inhibitor
|
| Phase III
|
BI 10773 | Diabetes mellitus type II | SGLT-2-antagonist | Inhibition of glucose transporter-2
|
| Phase III
|
BIBF 1120 (Vargatef
TM)
|
Primary indication:
Non-small cell lung cancer (NSCLC) |
Angiogenesis inhibition
|
Triple angiokinase inhibitor acting simultaneously on VEGFR, FGFR, PDGFR
|
| Phase III
|
BIBW 2992 | Primary indication:
Non-small cell lung cancer (NSCLC) |
Signal transduction inhibition
|
Dual
irreversible EGFR/HER2 inhibitor
|
| Phase III | Flibanserin
(Girosa®) |
Hypoactive
|
Serotonin receptor agonist and antagonist | Neurotransmitter modulator
|
| Phase II | Dabigatran etexilate
(Pradaxa®) |
Secondary prevention in acute coronary syndrome | Anticoagulation | Oral direct inhibition of Thrombin |
| Phase II
|
BI 6727
|
Variety of
cancer types |
Cell-cycle kinase inhibition | PLK-1 antagonist |
| Phase I
|
New compound
|
Variety of
cancer types |
Cell-cycle kinase inhibition |
Mitotic checkpoint inhibitor |
| Phase I | New compound | Diabetes mellitus type II
|
11ß-HSD-1-antagonist
|
|
* These are investigational agents; their safety and efficacy have not yet been established.
Status: Aug. 2010
